These are the most - and least - reputable drug companies in the world

GSK just welcomed the first female big pharma CEO onboard in 2017. With that, came a reshuffling of 40% of the company's top management team in a bid to bring in new ideas.

The drugmaker has seen increased competition in its core businesses: respiratory and HIV treatments. It entered into an open rivalry with Gilead over HIV drugs in November 2017.

In April, the company's shingles vaccine was recommended by the US Center for Disease Control.

However, in May, regulators in Europe and the US issued warnings about a link between the company's HIV drug, Tivicay, and certain birth defects. But just last month, the company's two drug HIV met goals in late-stage studies.

"At GSK, our purpose is to help people do more, feel better and live longer and we accomplish this with our innovative medicines and vaccines. We have a legacy of ensuring people have access to our medicines and our vaccines, and we lead the pharmaceutical industry in the fight against so-called super bugs – all of which has been recognized by the Access to Medicine Foundation," GSK said in an email statement to Business Insider.

Famous for drugs like Keytruda, Merck has had a bit of a comeback as a winner at ASCO with its positive melanoma data. But the company has had its share of bad headlines as well. In May 2017, Merck paid $60.2 million to resolve a lawsuit about its practices to delay entrance of generic drugs into the market. Merck was also accused that month of operating an anti-competition scheme. In August 2017, Trump called out Merck's CEO about lowering drug prices and increasing transparency in their operations. Merck, along with GSK and Pfizer were the only pharmaceutical companies to have a "weak" score, while the rest had "average" or "strong" reputations.

It's been a bumpy year for Mylan. The drugmaker faced scrutiny over its EpiPen recalls, followed by outcry over generic drug pricing. In June, however, Mylan scored a key approval for a biosimilar version of the drug Neulasta, which could help save the US billions.

Over the past year, Japanese drugmaker Takeda has been growing its global presence, first by sealing a deal with Ariad Pharmaceutics and then acquiring Shire, the maker of Adderall, for $64 billion.

The Israeli company is a huge manufacturer of generic drugs. In December 2017, it cut 25% of its workforce, but its stock got a bump in February after Warren Buffett declared a stake in it.

AZ, known for producing Crestor – a drug that treats high cholesterol and triglyceride levels – saw a win in lung cancer data in May this year, but suffered a setback from an Alzheimer's drug in June that failed to show signs of working.

Lilly is the producer of Cymbalta, a drug widely used for depression. The company was also part of the cohort that had to jump ship on its Alzheimer's drug.

The German pharmaceutical firm manufactures drugs not only for humans but for their pets as well. The company is now partnering up with some other big names to develop anti-diabetic medication.

BMS is making a big bet its new investments into immunotherapy-combination drugs for combating cancer.

Swiss drug company Roche is still one of the biggest in the world. In February, it acquired Flatiron Health, a cancer technology startup for $1.9 billion.

Amgen got a big win in May when the FDA approved its preventive migraine drug Aimovig, which is the first of a new class of medications that's going after the huge migraine market.

McKesson distributes not only drugs, but also health IT, medical supplies and care management tools. In June, the company reduced the CEO's pay by 10% after investors revolted.

The Danish company is known as a diabetes drug giant. The turbulent US market forced it to lay off 3,000 people and axe its long term growth plan.

The Botox-maker has had a rocky relationship with its investors this year. It's been actively refreshing its board, and just last month, it announced its plan to sell off two of its non-core businesses to appease investors. In June, the company presented positive data in a glaucoma candidate and meet goals with its oral migraine drug.

Gilead has historically been focused on antiviral drugs to treat diseases like HIV and hepatitis C. But earlier this year, it just made a huge bet on an experimental gene-editing technology for cancer treatments.

Best known for making aspirin, the German company is also throwing its hat in the ring to bet on gene therapies. In June, Bayer finalized its $66 billion merger with agriculture giant Monsanto, which has farmers worried.

The company specializes in treatments for neurodegenerative, blood-based, and autoimmune diseases. Althought it hasn't made many major moves this past year, it's still a major player when it comes to its neuroscience pipeline. Early this year, it sold its hemophilia drug maker company, Bioverativ, to Sanofi for $11.6 billion.

The Humira-maker spun out of of Abbott Laboratories back in 2013. Recently, its rheumatoid arthritis drug successfully completed a late-stage trial. AbbVie was ranked first in last year's list, but has fallen back a few spots this year.

Celgene specializes in drugs for cancer and inflammatory diseases, known for its treatment of multiple myeloma. However, in February, the company hit a major setback with its multiple sclerosis drug.

A subsidary of Roche, Genentech is investing in a new way to treat Alzheimer's. It also recently made a $534 million deal with Microbiotica to research gut bacteria in hopes of developing new treatments for inflammatory bowel disease.

Sanofi's winning characteristics lies in its promotion of ethics and transparency, according to Reputation Institute. Sanofi has in the past year promised to limit price increases and disclose "transparency reports" behind overall costs of its drugs.